Uncategorized

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The FDA weighs whether to approve a controversial new Alzheimer’s drug.

Read More

Catching America’s Top Cancer Killer

Doctors are pushing millions more Americans to get screened for lung cancer, but the test comes with tricky risks and tough barriers.

Read More

Calling the Shots: Should Employers Mandate COVID Vaccines?

We dig into the research to help employers weigh the pros and cons of requiring their employees to get vaccinated.

Read More

3 Employers, 2 Wonks and 1 Health Insurance Mess (LIVE!)

In this live episode, policy experts and employers debate the best way to improve employer-based health insurance.

Read More

Presenting The Dose: Asian Americans and the Dual Pandemic

The Commonwealth Fund’s Shanoor Seervai leads a discussion about anti-Asian bias and how the pandemic is affecting the lives of Asians in the U.S.

Read More

Public Option(al): What Happened to Biden’s Big Idea?

While states experiment with public health insurance options, federal action has stalled.

Read More

Preventing HIV Just Got A Lot Cheaper. What Took So Long?

After nearly a decade of sky-high prices, new generics have sent the price of the HIV prevention drug PrEP plummeting.

Read More

Biden’s $400 Billion Bet on Caring for Older and Disabled Americans at Home

President Biden wants to make a huge investment in an often neglected part of the health care system.

Read More

A New Era of Gun Violence Research

As gun violence surges, researchers use new federal funding to search for solutions.

Read More

No Simple Answers: A COVID Q&A With NYT’S Apoorva Mandavilli

We sit down with one of the top pandemic reporters in the country to answer listener questions.

Read More